

**Confidential**

**Date and Time: Wednesday 14<sup>th</sup> March 2012, 1000 - 1600**

**Minutes:** Confirmed

**Guideline Development Group Meeting**

**Place:** *National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ.*

**Present:** Alan Lobo, Consultant Physician & Gastroenterologist (Chair)  
 Adam Harris, Consultant Physician & Gastroenterologist  
 Jeremy Nightingale, Consultant General Physician & Gastroenterologist  
 (present from item 5 onwards)  
 Eshan Senanayake, General Practitioner  
 Assad Butt, Consultant Physician & Gastroenterologist (present from item 7  
 onwards)  
 David Bartolo, Consultant Colorectal Surgeon  
 Kerry Robinson, IBD Clinical Nurse Specialist  
 Valda Forbes, Gastroenterology & Hepatology Clinical Nurse Specialist  
 (present for items 1-4)  
 Sarah Cripps, Gastroenterology Pharmacist  
 Kate Kelley, Associate Director, NCGC  
 Nancy Pursey, Senior Project Manager, NCGC  
 Rachel Wheeler, Research Fellow, NCGC  
 Lola Adedokun, Health Economist, NCGC  
 Ralph Hughes, Senior health Economist, NCGC (present for items 1-3)

**Apologies:** Parastoo Karimi, Patient member  
 Nigel Westwood, Patient member  
 Bernard Higgins, Clinical Director, NCGC  
 Paul Miller, Senior Information Scientist, NCGC

**In attendance:**

NICE Staff:		
NICE attendee 1	Clifford Middleton	
NICE attendee 2		

**Observers:**

--	--	--

**Notes**

**1. Welcome and declarations of interest**

The chair welcomed the group to the sixth meeting of the ulcerative colitis guideline development group (GDG). The chair reviewed the declarations of interest register and deemed that Jeremy Nightingale would need to leave the room when recommendations

## Notes

were discussed due to a previously declared personal pecuniary interest. The chair requested updates to the declarations of interest register and no new interests were declared.

2. **Hazard ratios**  
A presentation was given on hazard ratios.
3. **Evidence review: oral ASAs and steroids for maintenance of remission**  
The GDG reviewed the evidence for oral ASAs and steroids for the maintenance of remission.
4. **Evidence review: immunomodulators for maintenance of remission**  
The GDG reviewed the evidence immunomodulators for the maintenance of remission.
5. **Evidence review: rectal steroids for maintenance of remission**  
The GDG reviewed the evidence for rectal steroids for the maintenance of remission.
6. **Evidence review: rectal ASAs for maintenance of remission**  
The GDG reviewed the evidence for rectals ASAs for the maintenance of remission.
7. **Other combinations of oral / rectal steroids and oral / rectal ASAs for maintenance of remission**  
The GDG reviewed the evidence for other combinations oral / rectal steroids and oral / rectal ASAs for the maintenance of remission.
8. **Monitoring of bone health**  
The GDG discussed and updated the protocol for the review question on bone health.
9. **GDG 4&5 meeting minutes**  
The GDG agreed the minutes were a true and accurate record of the meeting.
10. **GDG3 minutes**  
The minutes were agreed to be a true and accurate record of the meeting.
11. **Any other business**  
GDG8 will take place on 6<sup>th</sup> June 2012 as planned. Apologies were received from David Bartolo and Sarah Cripps.

## Date, time and venue of the next meeting

Tuesday 24<sup>th</sup> April 2012, from 1000 until 1600.  
Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ